Entresto Granted Expanded Indication in Chronic Heart Failure by FDA

Article Link: Entresto Granted Expanded Indication in Chronic Heart Failure by FDA

EAST HANOVER, N.J., Feb. 16, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of…

Source: FDA New Drug Approvals